

Press Release

ProStrakan Group plc

ProStrakan Announces Upcoming Launch of Abstral in France

Galashiels, Scotland, 30th June, 2009 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has completed the reimbursement pricing process with the French authorities for its pan-European breakthrough cancer pain product, Abstral, earlier than expected and, as a result, plans to launch this product in the important French market next month.

Abstral is a new formulation of fentanyl, a long-established opioid, used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for their chronic pain. In June 2008 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of Abstral across the European Union. ProStrakan received a marketing authorisation for Abstral from the French regulatory authority on 23rd February 2009.

Abstral will be marketed in France through ProStrakan's 17-strong sales force. France is viewed as an important market for Abstral as it is one of the largest existing fentanyl markets in Europe.

The French launch of Abstral follows on from the product's introduction in the UK and Germany where it has displayed strong growth since its launch in January 2009. In May 2009 ProStrakan reported that sales of Abstral in the UK and Germany had reached 7,200 tablets per week.

Commenting on the launch of Abstral in France, Dr Wilson Totten, ProStrakan's Chief Executive, said:

"Abstral is already starting to deliver on the considerable promise that we believe it has, both for patients suffering the debilitating effects of breakthrough cancer pain and for ProStrakan's continuing development. Its launch in France, earlier than planned, gives us further confidence in our target of achieving break-even for ProStrakan towards the end of 2009 and our first full year of profitability in 2010."

Ends

For more information on this announcement, please contact:

ProStrakan Corporate	+44 (0)1896 664000
Dr Wilson Totten, Chief Executive	
Paul Garvey, Chief Financial Officer	
Callum Spreng, Corporate Communications	

Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton	

Trout Group (for US investor enquiries)	
Gitanjali Jain	+1 (646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is situated in Galashiels in Scotland. The company's development capabilities are centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries.
www.prostrakan.com